Discontinue if paradoxical bronchospasm occurs. Not to be initiated during exacerbation or if patients have significantly worsening or acutely deteriorating asthma. Not intended for initial management of asthma. Not for use in acute asthma attacks. Risk of oropharyngeal fungal infections & dysphonia. Patients w/ active or quiescent pulmonary TB, fungal & viral infections in the airways; cardiac arrhythmias especially 3rd degree AV block & tachyarrhythmias, idiopathic subvalvular aortic stenosis, hypertrophic obstructive cardiomyopathy, severe heart disease, particularly acute MI, ischaemic heart disease, CHF, occlusive vascular diseases particularly arteriosclerosis, arterial HTN & aneurysm; thyrotoxicosis, DM, phaeochromocytoma & untreated hypokalaemia. Monitor serum K levels in severe & unstable asthma; blood glucose levels regularly. Avoid abrupt discontinuation of treatment. Transferring patients from oral to inhaled corticosteroids. Prolonged treatment w/ high doses may result in adrenal suppression & acute adrenal crisis. Not to be administered for at least 12 hr prior to anaesth. Not to be taken by patient w/ rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Hepatic or renal impairment. Not recommended during pregnancy. Lactation. Not recommended in childn & adolescent <18 yr.
Innovair Known or suspected congenital or drug-induced prolongation of QTc interval.
Innovair NEXThaler Pneumonia in patients w/ COPD. Systemic effects may occur eg, Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation (in childn & adolescents), decreased bone mineral density, cataract, glaucoma & more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression. Visual disturbance. Always have Innovair NEXThaler available for rescue use.
Sign Out
